Lipid assay improves cardiovascular risk prediction: Jeff Meeusen, Ph.D.
Jan 04, 2024•9 min•Ep. 272
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Jeff Meeusen, Ph.D., explains how Mayo Clinic Laboratories' new MI-Heart Ceramides assay helps guide the management of patients with mildly to moderately high cholesterol. The test measures levels of lipids beyond cholesterol that boost cardiovascular risk.
Show notes
(00:31)
Could you provide us a little bit about your background?
(01:20)
Could you give us a brief overview of this assay?
(02:45)
What patients should have this test and when should it be performed?
(04:25)
Could you talk a little bit about alternative test options and how they compare to our ceramides test?
(05:58)
Can you go a little bit further into how these results can impact patient care and how you may monitor patients in the future with this testing?
For the best experience, listen in Metacast app for iOS or Android